MONDAY, May 12, 2025 — A new study has found that people taking Eli Lilly’s obesity drug

2025年5月12日，星期一 —— 一项新的研究发现，服用礼来公司减肥药的人

Zepbound

泽普绑定

lost almost 50% more weight than those using Novo Nordisk’s

比使用诺和诺德的产品多减掉了近50%的体重

Wegovy

韦哥维

.

。

The study — published May 11 in the

该研究——发表于5月11日

New England Journal of Medicine

新英格兰医学杂志

— followed 751 people across the U.S. who were overweight or obese and had another weight-related health problem. None had diabetes,

——跟踪了美国751名超重或肥胖且存在其他与体重相关健康问题的人。他们均未患糖尿病，

The Associated Press

美联社

reported.

据报道。

Participants received weekly injections of either Zepbound (tirzepatide) or Wegovy (semaglutide).

参与者每周接受一次 Zepbound（替尔泊肽）或 Wegovy（司美格鲁肽）的注射。

After 72 weeks, people taking Zepbound lost an average of 50 pounds. Those on Wegovy lost about 33 pounds. That translated to a loss of about 20% of body weight for Zepbound users, compared to nearly 14% for Wegovy users.

72 周后，服用 Zepbound 的人平均减重 50 磅。而服用 Wegovy 的人减重约 33 磅。这意味着 Zepbound 用户的体重减轻了约 20%，而 Wegovy 用户则减轻了近 14%。

What's more, waist size also shrank by an average of 7 inches with Zepbound and about 5 inches with Wegovy.

此外，使用Zepbound后腰围平均减少了7英寸，而使用Wegovy后腰围平均减少了约5英寸。

The medications work by mimicking hormones that help regulate appetite and fullness. Zepbound targets two hormones (GLP-1 and GIP), while Wegovy targets only GLP-1,

这些药物通过模拟帮助调节食欲和饱腹感的激素起作用。Zepbound 靶向两种激素（GLP-1 和 GIP），而 Wegovy 仅靶向 GLP-1。

AP

美联社

reported.

已报告。

“Two drugs together can produce better weight loss,” said lead study author

“两种药物联合使用可以产生更好的减肥效果，”首席研究作者说。

Dr. Louis Aronne

路易斯·阿隆博士

of Weill Cornell Medicine. He presented the results Sunday at the European Congress on Obesity in Malaga, Spain.

威尔康奈尔医学院。他在西班牙马拉加举行的欧洲肥胖大会上展示了结果。

Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both groups, weight loss was about 6% lower in men than in women,

近 32% 的 Zepbound 用户减掉了至少四分之一的体重，而 Wegovy 用户中这一比例约为 16%。在这两组中，男性的体重减轻幅度比女性低约 6%。

AP

美联社

said.

说。

Both groups saw health improvements in blood pressure, blood sugar and blood fat levels, too.

两组的血压、血糖和血脂水平也都有所改善。

About three-quarters of study participants reported mild or moderate stomach issues, including nausea, constipation, diarrhea or vomiting.

约四分之三的参与者报告了轻度或中度的胃部问题，包括恶心、便秘、腹泻或呕吐。

In all, around 6% of Zepbound users and 8% of Wegovy users left the trial due to side effects,

总体而言，约6%的Zepbound用户和8%的Wegovy用户因副作用退出了试验，

AP

美联社

said in a report.

报告中说。

The drugs are popular. A 2024 KFF survey found that about 1 in 8 U.S. adults has used one of these medications. Zepbound sales totaled $4.9 billion worldwide last year, while Wegovy earned nearly $8.8 billion.

这些药物很受欢迎。2024年凯泽家庭基金会（KFF）的一项调查发现，大约每8个美国成年人中就有1人使用过其中一种药物。Zepbound去年的全球销售额总计达49亿美元，而Wegovy则赚得近88亿美元。

Both drugs were recently removed from the U.S. Food and Drug Administration's shortage list. Drugmakers have introduced programs to lower patient costs to $500 or less per month.

这两种药物最近都从美国食品药品监督管理局的短缺清单中移除。制药商已经推出了将患者每月费用降低至500美元或以下的计划。

However, CVS Health recently announced that Wegovy will be the preferred option on its list of covered drugs starting July 1, while Zepbound won't be.

然而，CVS健康公司最近宣布，从7月1日起，Wegovy将成为其医保覆盖药物清单上的首选药物，而Zepbound则不会。

“We’re going to need to use them all just because we have so many patients who need treatment,”

“我们需要使用所有（方法），因为我们有太多需要治疗的病人，”

Dr. Angela Fitch

安吉拉·菲奇博士

, chief medical officer of

，首席医疗官

knownwell

众所周知

, an obesity care company, said.

，一家肥胖症护理公司，表示。

She noted Wegovy has also been shown to cut the risk of serious heart problems by 20%.

她指出，Wegovy 还被证明可以将严重心脏问题的风险降低 20%。

The study was funded by Eli Lilly, maker of Zepbound.

这项研究由Zepbound的制造商礼来公司资助。

Whatever your topic of interest,

无论你感兴趣的话题是什么，

subscribe to our newsletters

订阅我们的新闻通讯

to get the best of Drugs.com in your inbox.

获取 Drugs.com 的最佳资讯到您的邮箱。